News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Chari A, Larson S, Holkova B, et al. Phase 1 trial of ibrutinib

Articles by Chari A, Larson S, Holkova B, et al. Phase 1 trial of ibrutinib

Study Summary: Ibrutinib Plus Carfilzomib for Relapsed or Relapsed/Refractory Multiple Myeloma

ByChari A, Larson S, Holkova B, et al. Phase 1 trial of ibrutinib,carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma [published online April 4, 2018]. Leuk Lymphoma. 2018:1-7. doi: 10.1080/10428194.2018.1443337.

October 18th 2018

Latest Updated Articles

$Study Summary: Ibrutinib Plus Carfilzomib for Relapsed or Relapsed/Refractory Multiple Myeloma$
Study Summary: Ibrutinib Plus Carfilzomib for Relapsed or Relapsed/Refractory Multiple Myeloma
October 18th 2018

Trending on AJMC

Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug

As GLP-1 Costs Climb, Medicare Part D Plans Face a Reckoning

ACO-SWITCH to Evaluate Tafamidis-to-Acoramidis Switch in ATTR-CM

Early Secukinumab Sustains Psoriasis Clearance a Year After Stopping

FAQ: Prior Authorization Reform—Will Changes Go Far Enough by 2027?